Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Veritone Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.42 (market cap $8.04B), while Veritone Inc trades at $1.08 (market cap $98.53M). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 81.6× Veritone Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Veritone Inc nearer its low. Which is the better fit depends on your goals.
| BIO | VERI | |
|---|---|---|
Market Cap | $8.04B | $98.53M |
Sector | Health | Technology |
52-Week High | $339.75 | $8.39 |
52-Week Low | $241.71 | $1.07 |
Enterprise Value | $7.85B | $130.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Veritone (VERI) trades at $1.10, down 6.78% in the last 24 hours, with a bearish technical signal despite oversold RSI readings. The company reported revenue of $92.19 million in 2025 but posted a net loss of $111.73 million, with negative profit margins and cash flow challenges. Recent news highlights multiple class action lawsuits alleging securities fraud, creating significant legal overhangs.
Investment outlook remains highly speculative given persistent losses and legal uncertainties. While analyst consensus shows mixed sentiment with 46% buy ratings, fundamental weaknesses and ongoing litigation pose substantial risks. The stock's current valuation at 0.88x sales offers limited protection against operational challenges and potential legal liabilities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
